Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BCT197 · 4 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| BCT197 | DRUG | Capsules will be taken orally with fluids over a 5 day period after randomization |
| Placebo | DRUG | Capsules will be taken orally with fluids over a 5 day period after randomization |
| Prednisone placebo | DRUG | capsules |
| BCT197 placebo | DRUG | capsules |
| Prednisone | DRUG | capsules |
| Itraconazole 200 mg | DRUG | Single dose of itraconazole |
| Azithromycin | DRUG | 3 daily doses of Azithromycin |
BCT197 is an investigational small molecule being developed for chronic obstructive pulmonary disease (COPD). It has been studied in Phase 2 clinical trials for the treatment of acute respiratory exacerbations of COPD. BCT197 is not approved and remains in clinical development.
BCT197 is being developed by Mereo BioPharma Group plc, a biopharmaceutical company traded on the NASDAQ under the ticker MREO. The drug is a small molecule therapeutic candidate in the respiratory area, currently in clinical development for chronic obstructive pulmonary disease.
BCT197 is in Phase 2 clinical development. Two Phase 2 trials studying BCT197 in patients with chronic obstructive pulmonary disease have been completed. The drug is investigational and has not received regulatory approval.
BCT197 has been studied in two completed Phase 2 trials: NCT01332097 and NCT02700919, both evaluating its safety and efficacy in COPD patients with exacerbations. Two Phase 1 drug interaction trials, NCT02926326 and NCT03498170, also completed, assessing effects of azithromycin and itraconazole on BCT197 exposure.
BCT197 is also known as BCT197A2201. One clinical trial, NCT01332097, titled 'Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation,' used this alternative name for the drug.